Welcome to our dedicated page for Galmed Pharmaceu SEC filings (Ticker: GLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals Ltd. filed a prospectus supplement that incorporates a Form 6-K disclosing an amended share purchase agreement and the closing of its acquisition of Colospan Ltd. on June 22, 2026. The amended terms replace $2.0 million equity at closing with additional cash so that total cash consideration at closing is $3,300,000. The agreement also provides for a performance-based earnout of up to $2,000,000 tied to cumulative Net Sales Revenues recognized beginning July 1, 2027: no payments on the first $5,000,000 of cumulative sales, 7% on sales between $5,000,000 and $12,000,000, and 9% on sales above $12,000,000, with an overall cap of $2,000,000. The earnout accelerates on a qualifying sale/license of Colospan or if Galmed completes equity financings aggregating at least $17,500,000 post-closing. The supplement also states up to 7,500,000 ordinary shares are covered by the prospectus for resale by YA II PN, LTD.
Galmed Pharmaceuticals completed its acquisition of Colospan Ltd. on June 22, 2026 under revised, less dilutive financial terms. Instead of issuing $2.0 million in Galmed shares at closing, Galmed will pay an aggregate $3.3 million in cash to Colospan shareholders and SAFE investors.
The deal also includes up to $2.0 million in performance-based earnout tied to cumulative Net Sales Revenues from July 1, 2027, with 7% on sales between $5 million and $12 million and 9% above $12 million, capped at $2.0 million and subject to acceleration on certain strategic events or equity financings totaling at least $17.5 million. Preliminary purchase price allocation reflects total consideration of $5.3 million, including approximately $4.9 million of goodwill and intangible assets, and 7.5% of the cash consideration held in escrow for 12 months.
Through Colospan, Galmed gains CG-100, a CE-marked intraluminal bypass device for colorectal surgery with supporting clinical data from 97 patients across four trials, positioning Galmed as a broader GI-focused medtech and biopharmaceutical platform.
Galmed Pharmaceuticals Ltd. filed Post-Effective Amendment No. 3 to its Form F-1 registration statement (Registration No. 333-289703) to file the consent of Brightman Almagor Zohar & Co. dated June 8, 2026 relating to audited financial statements of Colospan Ltd. The underlying registration covers the resale of up to 7,500,000 ordinary shares. No new securities are being registered and proceeds treatment is for selling holders.
Galmed Pharmaceuticals filed a prospectus supplement registering up to 7,500,000 ordinary shares for resale by YA II PN, LTD.
Separately, Galmed entered into a Share Purchase Agreement dated June 8, 2026 to acquire 100% of Colospan Ltd. Consideration includes $2,500,000 cash and $2,000,000 in Galmed ordinary shares (valued using the five-day average Purchaser Share Value). The SPA includes a 4.99% beneficial ownership blocker, an escrow holding 7.5% of each cash and share consideration for 12 months, and contemplates at least $6 million of investment in Colospan commercial expansion over 24 months. Closing is conditioned on Israeli procedural requirements (Section 341) and customary conditions, with closing expected in the second quarter of 2026.
Galmed Pharmaceuticals entered a Share Purchase Agreement to acquire all shares of Colospan Ltd., an Israeli medical device company focused on colorectal surgical care. Closing is expected in the second quarter of 2026, subject to customary conditions.
Galmed will pay $2.5 million in cash and issue $2 million of ordinary shares to Colospan shareholders and SAFE investors, with 7.5% of each held in escrow for 12 months. Galmed also plans to invest at least $6 million over 24 months after closing to build Colospan’s European and Israeli commercial footprint.
Colospan’s lead product, the CG-100 intraluminal bypass device, aims to reduce complications from anastomotic leaks in colorectal surgery. It holds CE Marking, Israeli approval, and FDA Breakthrough Device designation, with a pivotal PMA-supporting trial underway. Colospan remains pre-revenue, has an accumulated deficit, and its auditors highlight substantial doubt about its ability to continue as a going concern.
Galmed Pharmaceuticals Ltd. filed a Form 6-K highlighting new preclinical data from its collaboration with Tissue Dynamics on Aramchol Meglumine for cardiac fibrosis. Using human cardiac organoid models on the DynamiX® platform, researchers identified a previously unknown metabolic pathway linked to cardiac fibrosis and heart failure.
The combination of Aramchol Meglumine, an SCD1 inhibitor, with a selective PPARα agonist reduced fibrotic burden in inflammatory human cardiac organoids by approximately fourfold (p<0.001) while preserving heart muscle structure and metabolic function. A new patent application has been filed and preparations are underway for future IND-enabling activities, supporting Galmed’s strategy to expand Aramchol beyond liver disease into cardiometabolic and fibrotic indications.
Galmed Pharmaceuticals reported Phase 1 pharmacokinetics results for a new oral formulation of Aramchol meglumine (AM). A single 400mg AM dose increased Aramchol bioavailability by about 500% compared with a 300mg Aramchol free acid (AA) tablet, while a 200mg AM dose showed roughly threefold higher exposure.
The company views Study AM-001 as a pivotal step toward a once-daily 400mg AM regimen, supporting production of a GMP clinical batch, extended intellectual property protection, and a potential ~50% reduction in drug manufacturing costs. An additional PK study (AM-003) is ongoing, comparing 400mg AM tablets once daily with 300mg AA tablets twice daily.
Aramchol has previously shown reduced liver fat, attenuation of steatohepatitis, and anti-fibrotic effects at a 600mg dose in Phase 2 and Phase 3 (open-label) trials, with around 600 adults exposed so far. Galmed aims to advance Aramchol beyond MASH into gastrointestinal oncology and other cardiometabolic and neurological indications.
Galmed Pharmaceuticals Ltd. is collaborating with Tissue Dynamics Ltd. to develop a human-centered chronic cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoids to support discovery of new Aramchol-based therapies for complex fibrotic heart diseases.
The platform leverages Tissue Dynamics’ DynamiX® system, which can test more than 20,000 human cardiac organoids in parallel with continuous metabolic sensing and AI analysis. Galmed plans to apply its SCD1 and lipid-metabolism expertise to evaluate Aramchol-based candidates, combinations, and dosing strategies in chronic post-myocardial infarction and HFpEF-like settings.
Galmed Pharmaceuticals Ltd. is entering a research collaboration with Ramot at Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor Aramchol as a targeted therapy for metastatic brain cancers, particularly in p53-deficient tumors.
The project combines genomic expertise from the Ben-David Lab with advanced 3D in vitro and in vivo tumor models from the Satchi-Fainaro Lab to validate Aramchol’s efficacy and mechanism of action. Findings are also expected to support Galmed’s ongoing clinical work in colorectal cancers, while fitting the company’s strategy to extend Aramchol beyond liver disease into oncology and other cardiometabolic indications.
Galmed Pharmaceuticals reported a scientific milestone: a new brain-penetrating formulation of its SCD1 inhibitor Aramchol, co-developed with Barcode Nanotech. The formulation uses lipid nanoparticles and is designed for subcutaneous injection to cross the blood–brain barrier and reach the central nervous system.
In vitro studies showed that Aramchol dose-dependently down-regulated aggregation of the protein α‑synuclein, which is implicated in Parkinson disease, multiple system atrophy, dementia with Lewy bodies and other synucleinopathies. These disorders currently lack disease-modifying therapies, so a brain-targeted SCD1 inhibitor could represent a new treatment approach.
Galmed plans, subject to regulatory advice, to advance this brain-penetrant Aramchol into a proof-of-concept Phase 1b/2 study in Parkinson disease patients in H2 2026, extending its strategy beyond liver and cardiometabolic indications into chronic CNS diseases with high unmet need.